Health Catalyst, Inc.

Health Catalyst, Inc. Q1 FY2020 earnings

HCAT

Quarter ended Mar 2020.

← Q4 FY2019Q2 FY2020 →
Revenue
$45.1M
Operating margin
-40.1%
Net income
-$17.5M

Summary

HCAT reported total revenue of $45.1 million for the quarter ended March 31, 2020, up 28.1% from the prior-year quarter. Growth came from new customers and existing customers paying higher technology access fees under contractual annual escalators. The company also pointed to new offerings of expanded support services and professional services work tied to implementation, analytics, outsourcing, and other improvement services. Profitability went the other way. Operating loss widened to $18.1 million. Net loss widened to $17.5 million. Operating margin was -40.1%, down from the prior-year quarter. Diluted EPS was -$0.47. The losses included a sharp increase in stock-based compensation and costs tied to the Able Health acquisition.

Cash generation weakened. Operating cash flow was a use of $16.8 million, down from the prior-year quarter. Capital expenditures were $0.5 million, down from the prior-year quarter. Deferred revenue was $36.8 million at March 31, 2020. Remaining performance obligations were $49.9 million. The company ended the quarter with $204.6 million in cash, cash equivalents, and short-term investments. After the quarter closed, HCAT issued $230.0 million of 2.50% convertible senior notes due 2025. Net proceeds were $222.5 million. The company used $57.0 million to prepay all outstanding OrbiMed debt and paid about $21.6 million for capped calls. It also signed a South Jordan headquarters lease with about $31.7 million of future lease payments and more than $10.0 million of planned capital expenditure.

The revenue mix remains weighted toward technology. Technology represented 55% of total revenue and professional services represented 45%. Adjusted technology gross margin increased to 69% from 67%. Adjusted professional services gross margin decreased to 25% from 32%. Total adjusted gross margin was 49%, down from 52%. Adjusted EBITDA was negative $6.0 million, compared with negative $6.7 million in the prior-year quarter. Management said more than 90% of revenue is recurring. The company employed more than 900 team members. It is also integrating Able Health, which added transaction costs and a change in the fair value of contingent consideration. The acquisition led to a deferred tax benefit tied to a valuation allowance release.

Management did not provide quantitative guidance for the next quarter or the full fiscal year. Instead, it framed 2020 around COVID-19 uncertainty. The pandemic is expected to hurt new DOS Subscription Customer additions and the Dollar-based Retention Rate. HCAT may see lower Professional Services net retention and may discount services to support customers, which would pressure Adjusted Gross Margin. Any negative 2020 revenue impact from COVID-19 should reduce 2020 Adjusted EBITDA, though cost containment should partially offset the revenue hit. The company plans to bias cost cuts away from headcount. It also expects Adjusted Technology Gross Margin to decline near term as customers move to Microsoft Azure. Adjusted Professional Services Gross Margin may fluctuate or decline. Medicity customers are expected to produce flat to declining revenue. HCAT believes existing cash and its revolver are enough for at least the next 12 months. Tax risks include $269.1 million of federal NOLs and $215.2 million of state NOLs as of December 31, 2019, subject to ownership change limits.

The company has also developed technology and services solutions to support healthcare providers during the pandemic. It believes these offerings may help retain customers and acquire some new customers. Still, the near-term outlook depends heavily on how long the pandemic disrupts healthcare provider operations and spending. HCAT's revenue base is mostly recurring, but new customer additions and professional services work face clear pressure. The balance sheet was strengthened by the convertible notes, and the OrbiMed payoff removes the old term loan. Execution on the Azure transition and the Able Health integration will matter for margins and retention.

Forecast

Management guidance
2020
Total revenuenegative impact
Adjusted EBITDAnegative impact

Reported figures

GAAP, from SEC filings
MetricQ1 FY2020Q4 FY2019QoQQ1 FY2019YoY
Revenue$45.1M$43.5M+3.7%——
Research & development$13.1M$13.0M+0.3%——
Sales & marketing$13.5M$11.7M+15.2%——
General & administrative$9.7M$8.4M+15.8%——
Total operating expenses$39.2M$35.5M+10.3%——
Operating income (loss)-$18.1M-$13.7M-32.4%——
Operating margin-40.1%-31.4%-8.7 pp——
Net income (loss)-$17.5M-$14.3M-22.6%——
Net margin-38.8%-32.8%-6.0 pp——

Risks

HIGHMacroeconomic

The COVID-19 pandemic has disrupted healthcare providers, and MD&A states it will likely negatively affect new DOS Subscription Customer additions and Dollar-based Retention Rate over the coming months, with potential customer bankruptcies, delayed renewals, travel restrictions, and collection issues. The company cannot predict the duration or magnitude of the impact.

HIGHSales Cycle

The sales cycle for a new customer has averaged 11 months and in some cases exceeded 24 months; COVID-19 could lengthen it and delay revenue while operating expenses continue, and the company also cites long procurement cycles for large provider customers.

HIGHCompetition

The company competes with EHR vendors such as Epic Systems and Cerner and larger analytics companies such as Optum Analytics and IBM; these competitors may bundle analytics, have greater resources, and pressure pricing or cause customers to terminate contracts.

HIGHCloud Migration

Migration of customers from private data centers and on-premise deployments to Microsoft Azure is expected to increase cost of technology revenue and be a headwind against Adjusted Technology Gross Margin, even though Adjusted Technology Gross Margin increased from 67% for the three months ended March 31, 2019 to 69% for the three months ended March 31, 2020.

HIGHMargin Pressure

Adjusted Professional Services Gross Margin decreased from 32% for the three months ended March 31, 2019 to 25% for the three months ended March 31, 2020, and MD&A expects it may decline further from service mix, added headcount, and COVID-19-related discounted services, which could lower Total Adjusted Gross Margin.

HIGHDebt Obligations

In April 2020 the company issued $230.0 million of 2.50% Convertible Senior Notes due 2025 with net proceeds of $222.5 million and used $57.0 million to prepay OrbiMed debt; servicing, conversion, or repurchase may require significant cash, and the company has a history of net losses. For the quarter ended March 31, 2020, net loss widened to $17.5 million from $13.7 million in the prior-year quarter, down 27.5%, and operating cash flow decreased to $16.8 million used from $5.2 million used in the prior-year quarter, down 221.0%.

HIGHData Access

The Solution depends on data from third-party clinical, financial, and operational systems, and vendors may engage in information blocking; the 21st Century Cures Act Final Rule anti-information blocking provisions are not effective until November 2, 2020 with additional enforcement discretion, so access limitations could impair the Solution and enforcement could be costly.

MEDIUMTalent Retention

Several senior leaders are active members of the Church of Jesus Christ of Latter-Day Saints, and there is a risk they could receive a call to serve full-time; co-founder Steven Barlow has been on leave and his leave of absence will likely extend until August 2020, and loss of key personnel could disrupt operations.

MEDIUMMedicity Revenue

Medicity customers historically generated a lower Dollar-based Retention Rate than DOS Subscription Customers, and the company expects flat to declining revenue from Medicity customers in the foreseeable future, which could negatively impact revenue growth rates.

MEDIUMAcquisition Dilution

The company acquired Able Health in February 2020 and incurred $0.9 million in acquisition transaction costs in the quarter ended March 31, 2020; future equity issuance for earn-out targets ending December 31, 2020 could dilute stockholders and integration may require management attention.

LOWConcentration Risk

The three largest customers during 2019 comprised 4.6%, 3.6%, and 3.6% of revenue, or 11.8% in the aggregate, down from 17.5% in the aggregate during 2018; loss or renegotiation of a largest customer contract could adversely affect results.

Adjusted Technology Gross Profit
$16,969 thousand
Adjusted Technology Gross Margin
69%
Adjusted Professional Services Gross Profit
$5,071 thousand
Adjusted Professional Services Gross Margin
25%
Total Adjusted Gross Profit
$22,040 thousand
Total Adjusted Gross Margin
49%
Adjusted EBITDA
$(5,971) thousand

Adjusted EBITDA

23 quarters
-$6.0M
Q1 FY2020-29.3%

Adjusted Professional Services Gross Margin

16 quarters
25%
Q1 FY2020-12.0pp

Adjusted Technology Gross Margin

16 quarters
69%
Q1 FY2020+1.0pp

Total Adjusted Gross Margin

15 quarters
49%
Q1 FY2020-5.0pp

Adjusted Professional Services Gross Profit

9 quarters
$5.1M
Q1 FY2020-24.1%

Adjusted Technology Gross Profit

9 quarters
$17.0M
Q1 FY2020+17.2%

Total Adjusted Gross Profit

9 quarters
$22.0M
Q1 FY2020+4.2%

Summary, forecast, risks and KPIs are extracted from Health Catalyst, Inc.'s SEC filings for Q1 FY2020 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 21, 2026.